The analysis revealed that desmopressin might significantly decrease the frequency of nocturnal voids , nocturnal urine volume and nocturnal diuresis , potentially result ing in an extended duration of the first sleep period and improved sleep quality .
The adverse effects of desmopressin were similar to those observed in the placebo group .
Conclusions Administered desmopressin was an effective and well-tolerated treatment for nocturia
Purpose The purpose of this analysis was to evaluate the efficacy and safety of desmopressin for the treatment of nocturia .
Reducing nocturia in the elderly: a randomized placebo-controlled trial of staggered furosemide and desmopressin.
AIMS The purpose of this study was to investigate efficacy , safety , and impact on quality of sleep of staggered furosemide and desmopressin in the treatment of nocturia in the elderly . METHODS Patients aged > 60 years with nocturia at least two voids per night were screened for enrollment into the study . A 3-week dose-titration phase established the optimum desmopressin dose ( 0.1 , 0.2 , or 0.4 mg ) . After a 1-week " washout " period , patients who showed sufficient response during the dose-titration period were r and omized to receive staggered furosemide and the optimal dose of desmopressin or placebo in a double-blind design for 3 weeks . Voiding diaries were assessed before and after the treatment . RESULTS In all , 82 patients were r and omized to either staggered furosemide and desmopressin ( n=41 ) or placebo ( n=41 ) . In the study group , most patients reported a good response with both reduced nocturnal voids ( 3.5 vs. 2.0 , P<0.01 ) and urine volume ( 919.6 ml vs. 584.2 ml , P<0.01 ) . The mean duration of the first sleep period was improved by 70 min ( 133.6 vs. 203.2 , P<0.01 ) . Compared to placebo , staggered furosemide and desmopressin result ed in a significant reduction in the mean number of nocturnal voids ( 43 % vs. 9 % ; P<0.01 ) , nocturnal urine volume ( 37 % vs. 5 % ; P<0.01 ) , and increase in the mean duration of the first sleep period ( 52 % vs. 19 % , P<0.01 ) . Adverse events were mild . CONCLUSIONS Staggered furosemide and desmopressin provide an effective and well-tolerated treatment for nocturia in the elderly
The analysis revealed that desmopressin might significantly decrease the frequency of nocturnal voids , nocturnal urine volume and nocturnal diuresis , potentially result ing in an extended duration of the first sleep period and improved sleep quality .
The adverse effects of desmopressin were similar to those observed in the placebo group .
Conclusions Administered desmopressin was an effective and well-tolerated treatment for nocturia
Purpose The purpose of this analysis was to evaluate the efficacy and safety of desmopressin for the treatment of nocturia .